ELI LILLY & Co
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Olumiant (baricitinib) by Year
Olumiant (baricitinib) — Worldwide revenue ($M) [legacy separate disclosure] ($M)
Eli Lilly Olumiant (baricitinib): $957M in FY2024, up 3.8% from a year earlier. No newer figure appears in the documents we track.
Where the FY2024 figure comes from
Source: Form 10-K (filed 2025-02-19) ↗
Reported in Form 10-Q / 10-K Note 2 & MD&A (legacy separate product disclosure prior to FY2025 reorganization).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Olumiant (baricitinib) — Worldwide revenue ($M) [legacy separate disclosure] ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 957 | +3.8% | Form 10-K (filed 2025-02-19) ↗ |
| FY2023 | Dec 31, 2023 | 923 | +11.1% | Form 10-K (filed 2025-02-19) ↗ |
| FY2022 | Dec 31, 2022 | 831 | -25.5% | Form 10-K (filed 2025-02-19) ↗ |
| FY2021 | Dec 31, 2021 | 1,115 | +74.5% | Form 10-K (filed 2024-02-21) ↗ |
| FY2020 | Dec 31, 2020 | 639 | +49.7% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 427 | +110.8% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 203 | +342.1% | Form 10-K (filed 2021-02-17) ↗ |
| FY2017 | Dec 31, 2017 | 45.8 | – | Form 10-K (filed 2020-02-19) ↗ |
Breakdown
What makes up olumiant (baricitinib)
Cite this data
StockData. (2026). Eli Lilly Olumiant (baricitinib) ($M), annual FY2017–FY2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-olumiant-ww
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.